NEULANDLABPharmaceuticals
Neuland Laboratories Ltd — Profit & Loss Statement
₹12027.00
-1.94%
Neuland Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 19.14 Cr | -0.03 Cr | 0.66 Cr | -0.40 Cr |
| Tax Rate For Calcs | 0.25 | 0.25 | 0.24 | 0.22 |
| Normalized EBITDA | 340.80 Cr | 472.33 Cr | 276.20 Cr | 142.54 Cr |
| Total Unusual Items | 76.87 Cr | -0.12 Cr | 2.73 Cr | -1.81 Cr |
| Total Unusual Items Excluding Goodwill | 76.87 Cr | -0.12 Cr | 2.73 Cr | -1.81 Cr |
| Net Income From Continuing Operation Net Minority Interest | 260.11 Cr | 300.08 Cr | 163.52 Cr | 63.82 Cr |
| Reconciled Depreciation | 65.55 Cr | 59.70 Cr | 52.78 Cr | 49.04 Cr |
| Reconciled Cost Of Revenue | 750.51 Cr | 733.80 Cr | 613.79 Cr | 553.50 Cr |
| EBITDA | 417.67 Cr | 472.21 Cr | 278.93 Cr | 140.74 Cr |
| EBIT | 352.12 Cr | 412.51 Cr | 226.15 Cr | 91.70 Cr |
| Net Interest Income | 2.29 Cr | -5.77 Cr | -11.51 Cr | -12.50 Cr |
| Interest Expense | 5.79 Cr | 11.07 Cr | 10.40 Cr | 9.53 Cr |
| Interest Income | 10.58 Cr | 8.23 Cr | 1.56 Cr | 0.99 Cr |
| Normalized Income | 202.38 Cr | 300.17 Cr | 161.45 Cr | 65.23 Cr |
| Net Income From Continuing And Discontinued Operation | 260.11 Cr | 300.08 Cr | 163.52 Cr | 63.82 Cr |
| Total Expenses | 1.17K Cr | 1.11K Cr | 926.56 Cr | 827.24 Cr |
| Rent Expense Supplemental | 1.36 Cr | 0.92 Cr | 0.84 Cr | 0.71 Cr |
| Diluted Average Shares | 1.28 Cr | 1.28 Cr | 1.28 Cr | 1.28 Cr |
| Basic Average Shares | 1.28 Cr | 1.28 Cr | 1.28 Cr | 1.28 Cr |
| Diluted EPS | 202.74 | 233.89 | 127.45 | 49.74 |
| Basic EPS | 202.74 | 233.89 | 127.45 | 49.74 |
| Diluted NI Availto Com Stockholders | 260.11 Cr | 300.08 Cr | 163.52 Cr | 63.82 Cr |
| Net Income Common Stockholders | 260.11 Cr | 300.08 Cr | 163.52 Cr | 63.82 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 260.11 Cr | 300.08 Cr | 163.52 Cr | 63.82 Cr |
| Net Income Including Noncontrolling Interests | 260.11 Cr | 300.08 Cr | 163.52 Cr | 63.82 Cr |
| Net Income Continuous Operations | 260.11 Cr | 300.08 Cr | 163.52 Cr | 63.82 Cr |
| Tax Provision | 86.22 Cr | 101.36 Cr | 52.23 Cr | 18.34 Cr |
| Pretax Income | 346.33 Cr | 401.44 Cr | 215.75 Cr | 82.16 Cr |
| Other Non Operating Income Expenses | 20.51 Cr | 12.54 Cr | 0.52 Cr | 0.48 Cr |
| Special Income Charges | 69.19 Cr | -0.12 Cr | 2.73 Cr | -1.81 Cr |
| Other Special Charges | -69.19 Cr | 0.12 Cr | -2.73 Cr | 1.81 Cr |
| Net Non Operating Interest Income Expense | 2.29 Cr | -5.77 Cr | -11.51 Cr | -12.50 Cr |
| Total Other Finance Cost | 2.51 Cr | 2.92 Cr | 2.67 Cr | 3.96 Cr |
| Interest Expense Non Operating | 5.79 Cr | 11.07 Cr | 10.40 Cr | 9.53 Cr |
| Interest Income Non Operating | 10.58 Cr | 8.23 Cr | 1.56 Cr | 0.99 Cr |
| Operating Income | 266.58 Cr | 407.38 Cr | 234.34 Cr | 96.09 Cr |
| Operating Expense | 417.30 Cr | 374.48 Cr | 312.77 Cr | 273.74 Cr |
| Other Operating Expenses | 57.90 Cr | 44.46 Cr | 27.13 Cr | 26.12 Cr |
| Depreciation And Amortization In Income Statement | 65.55 Cr | 59.70 Cr | 52.78 Cr | 49.04 Cr |
| Amortization | 1.32 Cr | 1.06 Cr | 1.26 Cr | 1.48 Cr |
| Depreciation Income Statement | 64.22 Cr | 58.64 Cr | 51.52 Cr | 47.56 Cr |
| Selling General And Administration | 61.13 Cr | 52.86 Cr | 59.47 Cr | 43.09 Cr |
| Selling And Marketing Expense | 23.83 Cr | 21.95 Cr | 29.58 Cr | 27.40 Cr |
| General And Administrative Expense | 37.30 Cr | 30.92 Cr | 29.89 Cr | 15.69 Cr |
| Rent And Landing Fees | 1.36 Cr | 0.92 Cr | 0.84 Cr | 0.71 Cr |
| Gross Profit | 683.87 Cr | 781.87 Cr | 547.11 Cr | 369.83 Cr |
| Cost Of Revenue | 750.51 Cr | 733.80 Cr | 613.79 Cr | 553.50 Cr |
| Total Revenue | 1.43K Cr | 1.52K Cr | 1.16K Cr | 923.33 Cr |
| Operating Revenue | 1.43K Cr | 1.52K Cr | 1.16K Cr | 923.33 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Neuland Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.